Navigation Links
AMT Starts Development LPLChip(TM) With Progenika
Date:10/29/2009

AMSTERDAM, October 29 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) and Progenika Biopharma announced today that the companies have entered into a development and commercialization agreement for LPLchip(TM), a diagnostic tool to rapidly diagnose patients with complete and partial lipoprotein lipase deficiency (LPLD). AMT has developed Glybera(R) as a gene therapy for patients with this disease.

In June of this year AMT announced new clinical data showing that a one-time administration of its lead product Glybera(R) results in significant long-term health benefits for LPLD patients. Long-term follow-up data from two clinical trials with complete LPLD patients show that Glybera(R) therapy results in a significant and clinically important reduction in acute pancreatitis, the most debilitating complication of the disease. The data also confirm that the therapy is well-tolerated and safe. AMT intends to file Glybera(R) for marketing approval with EMEA by the end of this year.

LPLchip(TM) based on the Progenika's DNA-chip technology, will be used to rapidly diagnose patients with complete and partial LPLD and will be important to effectively identify patients that could benefit from Glybera (R).

AMT has selected Progenika as a partner for the development of LPLchip(TM) because of the company's long-standing expertise in the development of diagnostic chips and its access to both European and North American markets. Jorn Aldag, CEO of AMT commented: "We are delighted to work with Progenika on the development of the LPLchip(TM), as the company brings a unique expertise that fits the diagnostic needs for LPLD. LPLchip(TM) will be an important tool in early patient diagnosis, enabling us to make Glybera(R) available to the right patients as quickly as possible." Antonio Martinez, CEO of Progenika Biopharma said: "This collaborative project demonstrates how DNA-based diagnostics and highly targeted gene therapy can be combined to bring personalized medicine to patient groups whose medical needs were previously unmet."

About Progenika

PROGENIKA, a pioneering company in the emerging field of personalised medicine, is dedicated to the design, development and manufacture of novel DNA genotyping microarrays for the diagnosis, prognosis and drug-response prediction of complex human diseases. The company's comprehensive facilities for microarray design and manufacture are supported by an expert team of bioinformaticians who develop multivariate algorithms and software packages that allow user-friendly interpretation of clinical results. PROGENIKA has developed and clinically validated LIPOchip, a microarray for the diagnosis of Familial Hypercholesterolemia that was marketed in 2004, as the first CE-marked DNA microarray for routine clinical diagnosis. PHARMAchip, a Drug Metabolism genotyping microarray and BLOODchip, a Blood Group genotyping microarray were launched in 2007. A series of new diagnostic microarrays are under development or in late-stage clinical validation: fibromyalgia, inflammatory bowel disease, multiple sclerosis, rheumatoid arthritis, osteoarthritis, etc.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially those that are caused by one faulty gene. Currently, AMT has a product pipeline with nine products at different stages of development.

Certain statements in this press release are "forward-looking statements" including those that refer to management's plans and expectations for future operations, prospects and financial condition. Words such as "strategy," "expects," "plans," "anticipates," "believes," "will," "continues," "estimates," "intends," "projects," "goals," "targets" and other words of similar meaning are intended to identify such forward-looking statements. Such statements are based on the current expectations of the management of Amsterdam Molecular Therapeutics only. Undue reliance should not be placed on these statements because, by their nature, they are subject to known and unknown risks and can be affected by factors that are beyond the control of AMT. Actual results could differ materially from current expectations due to a number of factors and uncertainties affecting AMT's business, including, but not limited to, the timely commencement and success of AMT's clinical trials and research endeavors, delays in receiving U.S. Food and Drug Administration or other regulatory approvals (i.e. EMEA, Health Canada), market acceptance of AMT's products, effectiveness of AMT's marketing and sales efforts, development of competing therapies and/or technologies, the terms of any future strategic alliances, the need for additional capital, the inability to obtain, or meet, conditions imposed for required governmental and regulatory approvals and consents. AMT expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. For a more detailed description of the risk factors and uncertainties affecting AMT, refer to the prospectus of AMT's initial public offering on June 20, 2007, and AMT's public announcements made from time to time.

SOURCE Amsterdam Molecular Therapeutics B.V


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
2. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
3. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
4. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
5. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
6. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
7. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
8. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
9. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
10. Intercell Starts a Phase I Clinical Trial for a New Streptococcus pneumoniae Vaccine
11. BioCis Pharma Starts a Phase I Clinical Trial With a New Cancer Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... -- NDS received FDA 510(k) clearance in May 2017 for its highly ... designed for endoscopy environments. An innovative secondary monitor solution, ZeroWire ... support the improvement of patient outcomes, procedural efficiency, and the lowering ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/2/2017)... 2017  Eli Lilly and Company (NYSE: ... third quarter of 2017 on Tuesday, October 24, 2017. ... day with the investment community and media to further ... call will begin at 9 a.m. Eastern time. Investors, ... webcast of the conference call through a link that ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... Apple ... care services, staged a mock evacuation of the facility as part of a disaster ... Fire Department, Echo Hose EMS and Shelton City Emergency Manager, as well as the ...
(Date:10/13/2017)... , ... October 13, 2017 , ... Global Healthcare Management’s ... Alexandria Park in Milford, NJ. This free event, sponsored by Global Healthcare Management’s ... The fun run is geared towards children of all ages; it is a ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and ... plans to open a flagship location in Covington, LA at 401 N. U.S. Highway ... store next to Office Depot in the Holiday Square shopping center. Its location allows ...
(Date:10/12/2017)... ... 2017 , ... Asante, a nationally recognized health system in ... existing home health joint venture through an agreement, effective October 1, 2017, to ... home health company with Asante, delivering clinically integrated care, for the past eight ...
Breaking Medicine News(10 mins):